



Driscoll Health Plan

News and Updates



Date:

July-18
2025

Contact Information

For questions or additional assistance, contact:

Provider Relations
956-632-8308

To enter authorization requests and upload clinical via the Provider Portal, visit driscollhealthplan.com/providers

To verify authorization requirements via the Authorization Requirement Portal, visit driscollhealthplan.com/priorauthcheck

To submit authorization requests or clinical to the UM Dept. via fax, send to 1-866-741-5650

Attention: Authorization Requirement Updates

Effective 09/01/2025, DHP **will not** require prior authorization for the following procedure codes:

Clinician Administered Drugs:

- J9076, cyclophosphamide, indicated for the treatment of cancer and certain autoimmune disorders.
- J0165, epinephrine.
- J0168, epinephrine.
- J0616, metoprolol tartrate, treats high blood pressure.
- J0618, calcium chloride, treats low calcium levels.
- J1163, diltiazem hydrochloride, treats angina and high blood pressure.
- J9220, indigotindisulfonate sodium, a diagnostic dye for visualization of ureters during surgery.
- J2312, naloxone hydrochloride, rapidly reverses an opioid overdose.
- J2313, naloxone hydrochloride, zimhi, rapidly reverses an opioid overdose.
- J3373, vancomycin hydrochloride, antibiotic.
- J3374, vancomycin hydrochloride, mylan, antibiotic.
- J3375, vancomycin hydrochloride, Xellia, antibiotic.
- J9342, thiotepa, used to lower the risk of graft rejection as a preparative regimen for stem cell transplantation. It is also used to treat cancer of the breast, ovary, and urinary bladder.

Effective 09/01/2025, DHP **will not** require prior authorization for the following procedure codes for members 18 years and older:

Clinician Administered Drugs:

- C9174, treosulfan, a medication used in combination with fludarabine as a preparative regimen before an allogeneic hematopoietic stem cell transplant.
- J9289, nivolumab and hyaluronidase-nvhy, treats non-small lung, head, neck, colorectal, esophageal and gastric cancer.
- J9382, zenocutuzumab-zbco, to treat advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC) and pancreatic adenocarcinoma.
- J1326, zolbetuximab-clzb, a monoclonal antibody that targets a protein involved in certain types of cancer, restricted to members with at least one of the following diagnoses codes: C15.5, C15.8, C15.9, C16.0, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9.

* To access the DHP provider portal, visit driscollhealthplan.com